The nation of Zimbabwe has declined a major American healthcare agreement valued at 367 million US dollars (£272m) spanning five years due to Washington's demand for sensitive information.
This rejection was revealed following a government memo dated December was disclosed, revealing that President Emmerson Mnangagwa felt the deal was "skewed".
A government spokesman has since clarified that the US was requesting health data for research and profit but was unwilling to guarantee the benefits from future treatments.
"We will now turn to the difficult and regrettable task of scaling back our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had donated over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for further dialogue to find a agreement acceptable to all parties so the nation's vital HIV programme can proceed.
Wider Context
This development comes after a comparable case in Kenya, where a court suspended a related health funding agreement after legal challenges were filed about the security of citizens' medical information.
After resuming office recently, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump claimed its expenditure was "inefficient" and his government was seeking government-to-government agreements to boost openness and accountability.
As per statements, Sixteen nations in Africa have to date signed similar agreements, representing more than $18.3bn of fresh investment.
Details of the Rejected Deal
The money for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration would have delivered immense advantages for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy via American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"Our nation was requested to share its biological resources and data for a long time, without any equivalent assurance of benefiting from any medical innovations – such as new medicines or tests – that might be developed from that provided information," Mangwana explained.
"In essence, our nation would supply the raw materials for medical research without any assurance that the end products would be available to our citizens should a future pandemic arise."
National Interest and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending systems previously set up through the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to manage potential pandemics.
"This framework is intended to guarantee that when a country provides its information, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to create them."
The government's concerns regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage continued dialogue with our US partners on how future collaboration could be arranged in a manner that honours the sovereignty and dignity of each country."
Health Experts Response
A leading public health body expressed it recognised the government's concerns, but urged that talks should continue considering a large portion of the country's Aids initiatives were funded by international support.
"If specific concerns arise, including those relating to data governance or implementation frameworks, these can often be resolved via technical clarification and mutually agreed protections," it said.
The halted deal underscores the ongoing challenges between receiving much-needed international aid and protecting national sovereignty in an ever more data-driven world.